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AZT resistanceIt was recently proposed that HIV RT mutations that decrease RNase H activity increase zidovudine (AZT)
resistance by delaying the degradation of the RNA template, allowing more time for AZTMP excision from the
3′ end of the viral DNA. This predicts that suboptimal concentrations of an RNase H Inhibitor (RNHI), which
would decrease RNaseH activity, would decrease AZT susceptibility. Conversely, a suboptimal concentration
of a nonnucleoside RT inhibitor (NNRTI) would decrease polymerase activity and increase AZT susceptibility.
We determined the effect of several RNHIs and an NNRTI (nevirapine) on AZT and lamivudine (3TC)
susceptibility with vectors that replicate using WT or AZT resistant RTs. Susceptibility to 3TC, which is not
readily excised, did not change signiﬁcantly. Nevirapine, and most RNHIs tested, had only small effects on the
susceptibility of either HIV vector to AZT and 3TC. One RNHI, F0444-0019, increased the IC50 for AZT for either
vector by ~5-fold, which may be a concern.ram, National Cancer Institute,
ederick, MD 21702-1201, USA.
).
Inc.Published by Elsevier Inc.Introduction
The reverse transcriptase (RT) of HIV is the enzyme that converts
the single stranded viral RNA genome into the double stranded linear
DNA that is subsequently integrated into the host genome. RT has
two enzymatic activities that are essential for viral replication: a
polymerase activity that can copy either an RNA or a DNA template
and an RNase H activity that degrades RNA when it is part of an RNA/
DNA duplex. RNase H degrades the RNA template during the synthesis
of the ﬁrst DNA strand, setting the stage for the synthesis of the
second DNA strand. RNase H is also required for the two strand
transfer events that are needed for the synthesis of the viral DNA and
for the removal of the two RNA primers that are used to initiate minus
and plus strand DNA synthesis. Due to its critical role in the HIV life
cycle, RT is an important target for anti-HIV drugs. However, despite
the fact that there are two essential enzymatic activities, all of the
currently approved anti-RT drugs inhibit the polymerase activity.
Although the RNase H activity of RT is an attractive target for the
development of new anti-HIV drugs, no RNase H inhibitors (RNHI)
have made it into clinical trials.
There are two classes of approveddrugs that inhibit the polymerase
activity of RT: nucleoside reverse transcriptase inhibitors (NRTI) and
nonnucleoside reverse transcriptase inhibitors (NNRTI). NRTIs aredNTPs analogs that inhibit polymerization by being incorporated into
the growing DNA strand. Unlike the natural dNTP substrates, all of the
currently approved NRTIs lack a 3′ hydroxyl group; thus the incor-
poration of an NRTI blocks the extension of the viral DNA strand, a
process called chain termination. Mutations in RT that confer re-
sistance to NRTIs either increase the discrimination between the
triphosphate form of the NRTI and the dNTPs during DNA synthesis, of
which the best studied example is 3TC/FTC resistance caused by the
M184V/I mutations (Gao et al., 2000; Saraﬁanos et al., 1999), or, as
with most common AZT resistance mutations, increase the ATP-
dependent excision of AZTMP from the end of the viral DNA (Arion
et al., 1998; Boyer et al., 2001; Meyer et al., 1998, 1999). In contrast
to NRTIs, NNRTIs bind to a site near to the polymerase active site,
distorting the protein, and inhibiting the chemical step of polymer-
ization (Andries et al., 2004; Ding et al., 1995; Kohlstaedt et al., 1992;
Ren et al., 1995; Rittinger et al., 1995; Spence et al., 1995; Tantillo et al.,
1994).
Resistance to NNRTIs usually involves mutations in or near the
NNRTI-binding site, which interferes with the binding of the drugs in
the NNRTI-binding pocket [see (Saraﬁanos et al., 2004) or (Saraﬁanos
et al., 2009) for a review]. Although most of the primary mutations
that give rise to NRTI and NNRTI resistance are relatively near the sites
where the drugs bind, there are reports that mutations in the
connection (CN) subdomain, which is not close to the binding sites for
either NRTIs or NNRTIs, can enhance resistance to both NNRTIs and
NRTIs (Brehm et al., 2007; Ehteshami et al., 2008; Gupta et al., 2010;
Hachiya et al., 2008; Nikolenko et al., 2007, 2010; Yap et al., 2007;
Zelina et al., 2008).
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Fig. 1. Cell based luciferase assay measuring the effect of 40 nM NVP on the IC50 of AZT
in HOS cells infected with WT or AZT-R HIV. The average IC50 values±SD can be found
in Table 1. Assays were performed 7 times with WT HIV and 5 times with AZT-R HIV.
Table 1
The Effect of NVP on the IC50 of AZT and 3TC in HOS Cells infected with WT and AZT-R
HIV-1.
Virus AZT IC50 (nM±SD) Fold decreasea 3TC IC50 (μM±SD) Fold decreasea
–NVP +NVP –NVP +NVP
WT 4±3 3±1 1 8±3 4±1 2
AZT-R 41±38 21±11 2 24±14 15±3 ~2
a Not statistically signiﬁcant (pN0.05).
65C.A. Davis et al. / Virology 419 (2011) 64–71Modern highly active anti-HIV therapy (HAART) usually involves
two different NRTIs and either an NNRTI or a protease inhibitor. While
this combination therapy greatly decreases morbidity, long-term
treatment often has undesirable side effects, and HIV can develop
resistance to all of the available drugs. Given the emergence of drug
resistant variants of HIV, it is important to continue to develop new
inhibitors that would be effective against the existing resistant
variants. Because drugs that inhibit the polymerase activity of RT
are the backbone of most HAART therapies, it is important to consider
whether a new class of inhibitor, such as the RNHIs, would be
expected to enhance or diminish the effectiveness of any of the
commonly used polymerase inhibitors, and whether a new inhibitor
would be expected to have a positive or negative impact on resistance
to the existing drugs.
Recent evidence suggests thatHIV vectors that carrymutations that
reduce the level of RNase H activity have a reduced susceptibility to
AZT (Nikolenko et al., 2007); this result suggests that suboptimal
concentrations of RNHIs could increase AZT resistance. Conversely,
mutations that reduce the levels of the polymerase activity of RT are
expected to increase susceptibility to AZT, which would suggest that a
suboptimal concentration of an NNRTI should increase AZT suscepti-
bility. However, we tested the NNRTI nevirapine (NVP) and found that
suboptimal concentrations of NVP did not have a signiﬁcant impact on
the concentration of AZT required to inhibit HIV-1 replication by 50%
(IC50). Although a suboptimal concentration of most of the RNHIs we
tested did not signiﬁcantly affect the IC50 for AZT, the RNHI F0444-
0019 did cause a signiﬁcant decrease in AZT susceptibility (~5-fold),
which is similar to the decrease in susceptibility to AZT seen when CN
subdomain mutations were to added to NNRTI-resistant clinical iso-
lates (Gupta et al., 2010) of HIV-1 and to the contribution to resistance
made by CN subdomain mutations identiﬁed in clinical isolates
(Lengruber et al., 2011).
Results
The addition of NVP has little effect on the IC50 for AZT for either WT or
AZT-R vectors
We ﬁrst added suboptimal amounts of the NNRTI NVP to cells that
were subsequently infected with HIV to ask whether reducing the
amount of polymerase activity would change the IC50 for AZT. The
vectors used in these experiments either replicated using WT RT,
which has a modest ability to excise AZTMP, or an excision proﬁcient
AZT-R RT (see Methods) (Boyer et al., 2001). The HIV vectors lack a
functional Env coding region and were complemented with VSV-G,
which limits the infections to a single cycle. The HIV vectors express a
luciferase gene from the Nef reading frame; luciferase activity was
used to measure ability of the virus to infect the cells. With these
vectors, high level expression of luciferase requires that viral DNA is
reverse transcribed and integrated into the host genome. Before
studying the effect of NVP on AZT resistance, NVP was tested for its
ability to block the replication of the vectors. The WT or AZT-R HIV
vector was used to infect HOS cells in the presence of increasing
concentrations of NVP. Supplemental Fig. 1 shows that NVP blocks HIV
replication and has an IC50 of 36±17 nM for a one-round vector
expressingWT RT. The IC50 of NVP for blocking replication of the AZT-
R HIV vector was 27±1 nM (Supplemental Fig. 1). In subsequent drug
combination assays, 40 nM NVP was used to reduce the infectivity of
the virus stock by ~60%.
Using the same luciferase-based infectivity assay, the IC50 of AZT
was measured in the presence and absence of 40 nM NVP to
determine whether a decrease in polymerase activity would affect
AZT resistance. The IC50 of AZT for WT HIV was 4±3 nM in the
absence of NVP and 3±1 nM in the presence of 40 nM NVP, a neg-
ligible difference (Fig. 1 and Table 1). As shown in Fig. 1 and Table 1,
using AZT-R HIV, the IC50 for AZT was 41±38 nM and the IC50 wasreduced to 21±11 nM in the presence of 40 nM NVP, a difference of
only 2 fold. Although the absolute value of the IC50 for AZT did show
some drift over a period of several months, and this drift was seen in
independent experiments performed by several different people in
the laboratory (which accounts for the large standard deviations
shown here), the fold change in AZT IC50 caused by the addition of
either NVP or an RNHI (see below) was relatively constant.
Lamivudine (2′, 3′-dideoxy-3′-thiacytidine, commonly called
3TC), was used as a control in these experiments because it is not
readily excised by RT (Boyer et al., 2001; Naeger et al., 2002). Because
3TC is not efﬁciently excised by either WT or AZT-R HIV, the addition
of NVPwould be expected to have amoremodest effect on the IC50 for
3TC than the IC50 for AZT. Data presented here shows that the
presence of NVP slightly lowered the 3TC IC50 for either WT or AZT-R
HIV (~2-fold reduction for both, see Table 1 and Fig. 2), but the
differences were not statistically signiﬁcant. Thus, inhibiting the
polymerase by the amount needed to reduce the infectivity by ~60%
does not appear to have a large or speciﬁc effect on the susceptibility
of the vectors that replicate usingWT or the AZT-R RT to either 3TC or
AZT.Decreased RNase H activity may decrease AZT susceptibility
We next studied the effects of RNHIs on AZT susceptibility. To try
to minimize the possibility that an effect on AZT susceptibility was
due to an ancillary effect of the RNHI and not to the effect of the
compound on RNase H activity, we tested several different RNHIs. The
RNHI used in these experiments are shown in Fig. 3. All of these RNHIs
have been tested with recombinant HIV-1 RT in vitro and have been
shown to inhibit the RNase H activity, and are either less potent or
inactive against the polymerase activity of RT (Table 2).
Because cytotoxicity can affect HIV replication and drug suscep-
tibility, the RNHIs were tested for cytotoxicity in HOS cells using both
XTT and ATP based assays (see Methods). XTT, a tetrazolium
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Fig. 2. Luciferase assay measuring the effect of 40 nM NVP on the IC50 of 3TC in WT or
AZT-R HIV infected HOS cells. The average IC50 values±SD can be found in Table 1.
Assays were repeated 4 times with both WT and AZT-R HIV.
Table 2
In vitro inhibition of RT RNase H and DNA polymerase activities by RNHIs used in the
present study.
RNHI IC50 RT-RNase H (μM) IC50 RT-DNA polymerase (μM)
F0444-0019 5.0±1.8 18.5±5.9
F0888-0058 5.0±2.6 29.6±1.4
F0915-1507 5.8±2.2 N100
F3253-0041 2.9±1.1 N100
F3284-8495 3.3±0.7 N100
66 C.A. Davis et al. / Virology 419 (2011) 64–71derivative, is reduced to an orange colored product by mitochondrial
enzymes; the amount of orange product, quantiﬁed using a standard
microplate absorbance reader, is proportional to the number of
metabolically active cells. The concentration of RNHIs that would kill
half of the HOS cell population (CC50) was determined to be between
16 and 370 μM (see Table 3 and Supplemental Fig. 2). Because the
ability of the cells to convert AZT to AZTTP depends on ATP, the effect
of the RNHIs on the ATP levels was determined using a luciferase assay
in which the amount of light produced is proportional to the cellular
concentration of ATP. The ATP based luciferase assay indicated that
the CC50s for these RNHI were between 14 and 160 μM, as shown in
Table 3 and Supplemental Fig. 3.HO
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Fig. 3. Molecular structures of the RNase H inhibitors (RNHI) used in this study.Before studying the effect of the RNHI compounds on AZT re-
sistance, the IC50 values of each RNHI was determined in HOS cells for
the WT and the AZT-R vectors using the aforementioned luciferase
assay. Not surprisingly, the IC50s were similar for the two types of
vectors, as shown in Table 3 (see Supplemental Figs. 4 and 5). In most
cases the IC50s for these compounds were similar to the CC50 values
obtained in the cytotoxicity assays, and it is possible that some of the
decrease in infectivity is an indirect effect of the compound on the cell
rather than a direct effect on HIV replication. To help control for any
indirect effects of the RNHIs on HIV-1 replication and/or NRTI sus-
ceptibility, we also tested their effects on 3TC susceptibility. Because
we were concerned that the cytotoxicity of the compounds might
contribute to the anti-viral effect, we analyzed the effects of ﬁve
RNHIs. Because these are distinct compounds, we think it unlikely that
they would all have similar indirect effects on viral replication.
AZT susceptibility assays were performed in the presence the
RNHIs at concentrations that were near the in vivo IC50 for each
compound (20 μM for F0444-0019 and F0888-0058; 50 μM for F0915-
1507; 70 μM for F3253-0041 and F3284-8495). F0444-0019 caused a
moderate and signiﬁcant increase on the AZT IC50 for WT and AZT-R
HIV by ~5-fold; F0444-0019 also caused a small but signiﬁcant
increase in the IC50 for 3TC with WT HIV by ~3-fold (see Table 4;
Figs. 4 and 5). The effect of F0444-0019 on the 3TC IC50 in cells
infected with AZT-R HIV was insigniﬁcant. F0888-0058 had no
signiﬁcant effect on the IC50 of AZT (see Table 4) for WT HIV infected
cells. There was a signiﬁcant, but small (2-fold), effect of F0888-0058
on the AZT IC50 with AZT-R HIV infected cells; a very small, but
statistically signiﬁcant effect on 3TC susceptibility in cells infected
with theWT HIV vector (~1.7-fold). We did not see a signiﬁcant effect
on the IC50 for 3TC when the experiments were repeated with the
AZT-R HIV vector. F0915-1507 had no signiﬁcant effect on the IC50 for
AZT (see Table 4) for WT or AZT-R HIV infected cells; a similar lack of
effect was seen with 3TC. F3253-0041 and F3284-8495 had little to no
effect on the AZT IC50 withWT HIV and decreased the AZT IC50 in AZT-
R infected cells; however these assays were performed only one or
two times due to limited availability of the compounds and the small
effects on AZT susceptibility (Table 4). Because the impact of F3253-Table 3
The efﬁcacy and cytotoxicity of RNHI compounds against infection of HOS cells by WT
and AZT-R HIV. These assays were performed to determine the concentration of RNHI
needed to be used in subsequent AZT assays and were performed one or two times,
unless indicated, in order to conserve limited RNHI.
RNHI IC50 WT
HIV (μM)a
IC50 AZT-R
HIV (μM)
CC50
XTT (μM)b
CC50
ATP-lite (μM)
F0444-0019 24 28 24±3c 14±6 c
F0888-0058 34 30 16±5 c 14±3 c
F0915-1507 50 49 52 44±14
F3253-0041 70 59 370 160
F3284-8495 58 54 120 67
a IC50 values were determined using a luciferase based assay shown in Supplemental
Figs. 4 and 5.
b CC50 values were determined by measuring either the reduction of XTT by
mitochondrial enzymes or by measuring the concentration of cellular ATP, shown in
Supplemental Figs. 2 and 3.
c Assays were repeated in three or four independent experiments.
Table 4
The effect of RNHI on the efﬁcacy of AZT and 3TC in HOS cells infected with an HIV vector that replicates using either WT or AZT-R RT.
Drug +F0444-0019 +F0888-0058 +F0915-1507 +F3253-0041 +F3284-8495
AZT IC50 (nM±SD)
WT 4±3 19±17a 8±7 8±8 5b 4.8b
AZT-R 41±38 207±92a 83±58a 66±45 9.6b 8.5b
3TC IC50 (μM±SD)
WT 8±3 25±7a 12±3a 10b Not determined Not determined
AZT-R 24±14 45±29 13±10 43b Not determined Not determined
a Indicates that the RNHI has a signiﬁcant effect on the AZT or 3TC IC50 (pb0.05) as determined by performing a Mann–Whitney Rank Sum Test.
b These experiments were performed only one or two times due to either a small effect or limited availability of the RNHI compounds.
67C.A. Davis et al. / Virology 419 (2011) 64–710041 and F3284-8495 on AZT resistance was small, we did not test its
effects on 3TC susceptibility.
Because these RNHI were cytotoxic and treatment reduced the
level of ATP in the cells, it is possible that some or all of the RNHIs
reduced the level of ATP, which in turn led to a reduction in the
amount of AZTTP in the cells. This could mean that part or all of the
decrease in AZT susceptibility, seen with compound F0444-0019,
could be due to an effect on the concentration of AZTTP rather than an
effect on the RNase H activity of RT. To test this possibility, we used
the mitochondrial toxin sodium azide (NaN3) to reduce the level of
ATP in the HOS cells. The cytotoxicity of NaN3 in HOS cells wasWT HIV
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Fig. 4. Cell based luciferase assay measuring the effect of 20 μM F0444-0019 on the IC50
of AZT in HOS cells infected with WT (A) or AZT-R (B) HIV. The IC50 values±SD can be
found in Table 4. Assays were performed 6 times with WT HIV and 4 times with AZT-R
HIV.determined using both XTT and ATP based luciferase assays, as shown
in Supplemental Fig. 6. The addition of 0.5 mMNaN3 reduced the level
of ATP in the HOS cells by ~70% (see Table 5). The concentration of
most RNHI compounds used in the AZT (and 3TC) experiments
reduced the levels of ATP by ~60% relative to untreated cells, as shown
in Table 5, with two compounds reducing ATP levels by about 10%. The
addition of 0.5 mM NaN3 to HOS cells prior to HIV infection had no
signiﬁcant effect on the IC50 for AZT with WT or AZT-R HIV (Fig. 6;
Table 6). Thus, the data suggest that the effect of the one RNHI that
had a signiﬁcant effect on the IC50 of AZT (F0444-0019) is not due to aWT HIV
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Fig. 5. Cell based luciferase assay measuring the effect of 20 μM F0444-0019 on the IC50
of 3TC in HOS cells infected with WT (A) or AZT-R (B) HIV. The IC50 values±SD can be
found in Table 4. Assays were performed 3 times with WT HIV and 4 times with AZT-R
HIV.
Table 5
The amount of ATP in cells treated with NaN3 or a RNHI relative to untreated HOS cells as determined by an ATP-based luciferase assay.
0.5 mM
NaN3
20 μM
F0444-0019
20 μM
F0888-0058
50 μM
F0915-1507
70 μM
F3253-0041
70 μM
F3284-8495
% ATP relative to untreated HOS 31±8 36±10 41±4 46a 92a 87a
a ATP assays repeated only one or two times.
68 C.A. Davis et al. / Virology 419 (2011) 64–71decrease in the level of ATP, which, in turn, led to decrease in the
concentration of AZTTP. The interpretation that F0444-0019 has an
effect on AZT susceptibility that is not simply due to an effect on the
ATP concentration (and its impact on NRTI phosphorylation) is also
supported by the fact that this RNHI has a greater effect on AZT
susceptibility than it has on 3TC susceptibility; like AZT, 3TC must be
converted to its triphosphate to be active.
Discussion
Combination drug therapy is the standard of care for HIV
infections. Any new compounds that are developed will be used in
combination with the existing ﬁrst-line drugs. For this reason it is
important to understand whether a new drug will interact with the
existing drugs, either in a positive or a negative way, and to
understand the mechanisms by which HIV can evade the drug. ForWT HIV
WT HIV + NaN3
WT HIV
WT HIV + NaN3
A
bs
ol
ut
e 
In
fe
ct
iv
ity
100
80
60
40
20
0
R
el
at
iv
e 
In
fe
ct
iv
ity
100
80
60
40
20
0
403020100
AZT (nM)
403020100
AZT (nM)
A
C
Fig. 6. Luciferase assays measuring the effect of 0.5 mM NaN3 on the IC50 of AZT in HOS cells
infectivity and C) and D) depict the relative infectivity of HIV in the presence and absence of
WT and 8 times with AZT-R HIV.instance, it has been reported that NNRTIs and NRTIs act in a
synergistic manner to inhibit HIV replication (Basavapathruni et al.,
2004; King et al., 2002), thus making AZT a more effective anti-HIV
drug if it is given in combination with an NNRTI. The recent data
showing that there is interplay between the levels of RNase H activity
and polymerase activity can affect the efﬁciency of AZT excision and,
by extension, AZT resistance could potentially offer an explanation for
this reported synergy (Brehm et al., 2007; Ehteshami et al., 2008;
Nikolenko et al., 2007, 2010).
The model proposed by Nikolenko et al. (Nikolenko et al., 2007)
postulates that a decrease in thepolymerase activity (including adecrease
caused by an NNRTI) would allow the RNase H activity to degrade the
template before the polymerase could excise the AZTMP from the end of
the template. Themodel also suggests what affect RNase H inhibitors will
have on AZT excision. Recent work showing that themutations in the CN
subdomain of RT can enhance AZT resistance (Brehm et al., 2007;AZT-R HIV
AZT-R HIV + NaN3
AZT-R HIV
AZT-R HIV + NaN3
100
80
60
40
20
0
100
120
80
60
40
20
0
4003002001000
AZT (nM)
4003002001000
AZT (nM)
B
D
infected with A) and C) WT and B) and D) AZT-R HIV. A) and B) represent the absolute
NaN3. The IC50 values±SD can be found in Table 6. Assays were repeated 6 times with
Table 6
The Effect of NaN3 on the IC50 of AZT in HOS Cells Infected with WT and AZT-R HIV-1.
Virus AZT IC50 (nM±SD) Fold
decreasea
–NaN3 + NaN3
WT 4±3 4±2 0
AZT-R 41±38 56±37 1.4
a Not statistically signiﬁcant (pN0.05).
69C.A. Davis et al. / Virology 419 (2011) 64–71Ehteshami et al., 2008; Hachiya et al., 2008; Nikolenko et al., 2007; Yap et
al., 2007; Zelina et al., 2008) suggests that RNase H inhibitors should
decrease susceptibility to AZT, and that NNRTIs should increase AZT
susceptibility. Nikolenko and coworkers analyzed the effect of patient-
derived C-terminal domains (CTD) of HIV-1 RT on AZT resistance and
showed that mutations in the CN subdomain of RT which reduced RNase
H activity also caused a decrease in susceptibility to AZT (from11- to 536-
fold compared with WT RT) when the RT also contained AZT resistance
mutations; however, a substantial portion of this decrease was caused by
the AZT resistance mutations (discussed below) (Nikolenko et al., 2007).
The model predicts that mutations that decrease polymerase activity
relative to RNase H activity will have the opposite effect.
However, we found that there was relatively little difference (1–2
fold) in the AZT IC50 in single round infectionswhenNVPwas added at a
concentration which inhibited ~60% of viral replication. Nor was the
magnitude of the effect on AZT susceptibility signiﬁcantly greater when
the experiments were repeated with vectors that replicate using AZT-R
RT,which exciseAZTmore efﬁciently thanWTRT. Althoughwedid see a
small effect on the IC50 for AZTwith both theWT and the AZT-R vectors,
we saw a similar small effect when the same experiments were
performed with 3TC. Because, in contrast to AZT, 3TC is poorly excised
by bothWTRT and AZT-R RT, this effect cannot be easily explained as an
effect on the rate of polymerization and/or excision relative to the
degradation of the RNA template that would lead to a decrease in 3TC
excision. The 3TC data raise the possibility that the same unknown
mechanism could explain the small effect of NVP on the IC50s for AZT
and 3TC, and by extension, the possibility that the small effect seen here
with AZT does not involve the NVP altering the rates of polymerization
and/or excision relative toRNAdegradation. Even if theeffects ofNVPon
AZT susceptibility are due to a differential effect on excision that is
caused by a decrease in the polymerase activity relative to RNase H
activity, the effects on AZT resistance are relatively small, suggesting
that reducing polymerase activity has only a modest effect on AZT
excision. Others have shown that, in addition to inhibiting the chemical
step of polymerization, NNRTIs can also affect RNase H cleavage
speciﬁcity (Palaniappan et al., 1995) and/or activity (Gopalakrishnan
and Benkovic, 1994; Hang et al., 2007; Radzio and Sluis-Cremer, 2008;
Shaw-Reid et al., 2005): thus, NNRTIs that have an effect on the RNase H
activity as well as the polymerase activity could potentially affect the
synergy betweenNRTIs andNNRTIs in a complexway. The real concern,
however, is not that combining an NNRTI with AZT, or other NRTIs that
can be excised by mutant RTs, would increase the susceptibility of the
virus to the drug; this would, from the point of view of treating HIV
infections, be a good, not a bad, outcome. The more serious concern is
that a suboptimal doseof anRNHImightmimic the effects of someof the
CN subdomain mutations, and cause a reduction in the susceptibility to
AZT. Althoughwe found that one of the compoundswe tested did cause
a signiﬁcant decrease in susceptibility to AZT, the magnitude of the
effect was modest (about 5-fold). However, even if an increase in the
IC50 for AZT of 5-fold is less thanwhat has been reported for some of the
CN subdomain mutations (Nikolenko et al., 2007), it is still an
undesirable outcome, particularly because a 5-fold loss in AZT
susceptibility can cause clinical resistance. In terms of what is the
expected amount of the reduction in AZT susceptibility from a CN
subdomain mutation, when clinical isolates of drug-resistant RTs are
modiﬁed to contain speciﬁc CN subdomainmutations the change inAZTsusceptibility varies, and it would appear that the fold-change in
susceptibility depends on the exact nature of the drug-resistance
mutations that the clinical isolates carry (Gupta et al., 2010). The fold-
increase in AZT resistance caused by the addition of either the N348I or
the T369I mutation ranged from approximately 3.5-fold to more than
25-fold (Gupta et al., 2010). A similar observation was made when CN
subdomain mutations that were associated with other AZT resistance
mutationswere placed in the context ofWT or AZT-RHIV (Lengruber et
al., 2011). If these are representative numbers, the 5-fold decrease in
AZT susceptibility we report for F0444-0019 could be considered to be
similar to the effect of adding one of the CN subdomainmutations to the
clinical isolates. The relative modest effects of nevirapine on the IC50 for
AZT also suggests that perturbing the ratio of RNase H and polymerase
activity does not, by itself, necessarily cause a large change in the
susceptibility of HIV to NRTIs.
We think it is likely that at least someof the CNmutations can have a
direct effect on AZT resistance either in addition to, or instead of, their
impact onRNaseH activity because the recent publication fromDelviks-
Frankenberry et al. (Delviks-Frankenberry et al., 2008) reported that
some of the effects of the CN domainmutations on AZT resistance could
be attributed to an effect on the polymerase site (that is to a direct effect
on AZTMP excision) rather than to an effect that depended solely on a
reduction in RNase H activity. That could help to explain what is
otherwise a rather puzzling observation: the secondary mutations that
have been observed in viruses isolated from patients that enhance AZT
resistance are found in the CN subdomain, but not in the RNase H
domain.We have no simple explanation for the smaller, but signiﬁcant,
impact of F0444-0019 on 3TC susceptibility. As has already been
discussed, 3TC is poorly excised, and we do not believe that the change
in 3TC susceptibility was caused by a change in the ATP levels.
If F0444-0019 caused a 5-fold change in the AZT susceptibility of
HIV, and if this is the kind of effect on AZT susceptibility an RNHI
should cause, why then did we not see similar effects with all of the
other RNHIs? It is important to note that, unlike most of the RNHIs
tested in this study, F0444-0019 also has some inhibitory activity
against DNA polymerase activity of RT, albeit much less than that
against the RT-RNase H activity (Table 3). Although it is possible that
the inhibitory effect of F0444-0019 on the polymerase activity of RT
could have affected the results we obtained, as has already been
discussed, a reduction in the polymerase activity of RT would be
expected to enhance the susceptibility of the virus to AZT, not reduce
it. We also suspect, but cannot prove, that the toxicity of some of the
compounds may play a factor in the observed phenotype. Reducing
the RNase H activity of RT has been shown to reduce the susceptibility
of HIV to AZT (Nikolenko et al., 2007); however, as the NaN3
experiments showed, treating the cells with a toxic compound does
not. The primary reason that we performed experiments with several
RNHIs was because we knew the compounds were toxic; by testing
several compounds we could ask if any of the compounds would
signiﬁcantly shift the IC50 for AZT.
From the point of view of drug development, the primary issue is the
observation that one of the compounds tested caused a ﬁve-fold
decrease inAZT susceptibility. Although this increase inAZT resistance is
less than has been reported for some of the CN subdomainmutations, it
is still sufﬁcient to cause a clinically signiﬁcant resistance to AZT, and is,
for that reason, a potentially serious concern, particularly given the
importance of combination therapy in the treatment of HIV infections.
Methods
Reagents
The human embryonic kidney cell line 293Twas obtained from the
GenHunter Corporation (Nashville, TN). The human osteosarcoma cell
line (HOS) was obtained from Dr. Richard Schwartz (Michigan State
University, LansingMI). Cells were maintained in Dulbecco's modiﬁed
70 C.A. Davis et al. / Virology 419 (2011) 64–71Eagle's medium supplemented with 3.5% (vol/vol) fetal bovine serum,
3.5% (vol/vol) newborn calf serum, and penicillin (100 μg mL−1) plus
streptomycin (100 μg mL−1) (Quality Biological, Gaithersburg, MD).
AZT and 3TC were obtained from Moravek (Brea, CA). NVP was
provided by Dwight Nissley (NCI-Frederick). The compounds that
were identiﬁed as inhibiting RNase H activity were purchased from
Life Chemicals (Burlington, ON, Canada).Virus production
Replication defective HIV was produced in 293T cells. 10–15 μg of
DNA encoding the HIV-1 vector pNLNgoMIVR-Emod Luc (described in
Ferris et al. (2010); Julias et al. (2001)) was transfected, along with
3 μg of a VSV-G envelope expression plasmid (pHCMVg obtained from
Dr. Jane Burns, University of California, San Diego), by the calcium
phosphate method (Graham and van der Eb, 1973). The two versions
of the pNLNgoMIVR-Emod Luc that were used expressed either a WT
RT or an AZT resistant variant of RT, referred to here as AZT-R HIV,
which contained the following mutations: M41L, D67N, K70R, T215Y
and K219Q. Virus containing supernatants were harvested 36–48 h
after transfection and the supernatants were centrifuged to remove
debris. The virus was treated with DNase I for 1 h at 37 °C and stored
at −80 °C.Drug assays
In vitro RT-RNase H activity as assessed using wt HIV-1 RT as
previously described (Parniak et al., 2003). In vitro RT RNA-dependent
DNA polymerase activity was evaluated as previously described
(Song et al., 2008). In vivo assays were performed in HOS cells, which
were plated in 96 well luminescence cell culture plates at a density of
4000 cells in 100 μL media per well the day prior to infection. On the
day of infection, cells were treated with various concentrations of
a drug or control (media/DMSO) 3 h prior to the addition of the HIV
vectors that replicated using either the WT or AZT-R RT. Luciferase
assays were performed as previously described (Comin et al., 2008).
AZT assays +/− NNRTI or RNHI were performed in parallel in a mini-
mum of three independent experiments unless otherwise indicated.
Data was ﬁt to a single exponential decay and subject to the Mann–
Whitney Rank SumTest using SigmaPlot 11.0. To obtain the IC50 values
for the RNHI used here, the rawdatawasﬁt to a 4-parameter sigmoidal
binding model using SigmaPlot 11.0.Cytotoxicity and cell viability assays
Cytotoxicity assays were performed by measuring in vivo ATP
concentrations as described (Comin et al., 2008). Cell viability was
determinedusing theXTT cell viability assay kit (Biotium, Inc) according
to the manufacturer's instructions.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.08.010.Acknowledgments
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